Tag: ATH434

Phase-II of the ATH434 trial for multiple system atrophy patient dosing has started, according to Alterity Therapeutics.

The first participant in Alterity Therapeutics’ phase 2 clinical trial of ATH434 in multiple system atrophy (MSA), a rare and severely handicapping Parkinson’s disease, has been dosed in the US, according to the biotechnology company’s announcement. Alterity Therapeutics is dedicated…

Back to top

This will close in 0 seconds

Registration Form


This will close in 0 seconds